What the Eczema Area and Severity Index Score Tells Us About the Severity of Atopic Dermatitis: an Interpretability Study
Overview
Authors
Affiliations
Background: The Eczema Area and Severity Index (EASI) is an investigator-assessed instrument measuring the severity of clinical signs in atopic dermatitis (AD). The EASI was identified as one of the best-validated outcome measures for AD; however, no previous studies address how to interpret the EASI score for clinical use.
Objectives: To evaluate the interpretability and the ease of use of the EASI.
Methods: A retrospective analysis of paediatric and adult patients with AD was performed. Interpretability was evaluated by stratifying the EASI scores according to the Investigator's Global Assessment. The severity strata displaying the highest kappa coefficient of agreement were then selected as the recommended EASI band. The time to administer the EASI was recorded in a subgroup of patients.
Results: The suggested severity strata for the EASI are as follows: 0 = clear; 0·1-1·0 = almost clear; 1·1-7·0 = mild; 7·1-21·0 = moderate; 21·1-50·0 = severe; 50·1-72·0 = very severe (κ = 0·75). The EASI was also found to be acceptable in terms of ease of use, with assessments by trained investigators taking approximately 6 min.
Conclusions: Our study provides the first guide for interpreting the EASI score. It enables translation of the EASI numerical output into an AD global severity state that should be more meaningful to providers and patients. Along with a short administration time, the EASI demonstrates adequate feasibility, further supporting its use in clinical trials.
Silverberg J, Anderson P, Cappelleri J, Piercy J, Levenberg M, Myers D Arch Dermatol Res. 2025; 317(1):556.
PMID: 40072609 PMC: 11903610. DOI: 10.1007/s00403-025-03910-y.
Roads to remission: evolving treatment concepts in type 2 inflammatory diseases.
Lommatzsch M, Blumchen K, Beck L, Bousquet J, Brusselle G, Fokkens W EClinicalMedicine. 2025; 80:103050.
PMID: 39867971 PMC: 11764424. DOI: 10.1016/j.eclinm.2024.103050.
Tayefi M, Svedbom A, Ivert L, Lundqvist M, Ruas J, Bradley M Acta Derm Venereol. 2024; 104:adv40796.
PMID: 39545373 PMC: 11586677. DOI: 10.2340/actadv.v104.40796.
Nakahara T, Noto S, Matsukawa M, Takeda H, Zhang Y, Kondo T Dermatol Ther (Heidelb). 2024; 14(11):3113-3132.
PMID: 39487325 PMC: 11557786. DOI: 10.1007/s13555-024-01300-2.
Alradaddi A, Al Twaim A, Abu-Aliat A, Al-Atass K, Alogayell L, Aldayil M Dermatol Res Pract. 2024; 2022:5636903.
PMID: 39444785 PMC: 11496595. DOI: 10.1155/2022/5636903.